Comparative Pharmacology
Head-to-head clinical analysis: AQNEURSA versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQNEURSA versus POKONZA.
AQNEURSA vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQNEURSA is a monoclonal antibody that binds to and inhibits the activity of serum amyloid A (SAA), reducing amyloid deposition in tissues.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
AQNEURSA (ursodiol) is administered orally at 13–15 mg/kg/day in 2–4 divided doses for primary biliary cholangitis. For gallstone dissolution, the dose is 8–10 mg/kg/day in 2–3 divided doses, with a maximum of 300 mg twice daily.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe cases).
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Approximately 70-80% of the dose is excreted renally as unchanged drug; 20-30% is eliminated via biliary/fecal routes.
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid